Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560859 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDLRRK2GAAMEN1 | |
| SCHEMBL17560941 | 0.84 | GAA (0.58) | SMN1; SMN2HPGDLRRK2GAAMEN1 | |
| SCHEMBL17560934 | 0.84 | GAA (0.58) | SMN1; SMN2HPGDLRRK2GAAMEN1 | |
| SCHEMBL17581319 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HPGDLRRK2GAAMEN1 | |
| SCHEMBL16224338 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HPGDLRRK2GAAMEN1 | |
| SCHEMBL19434754 | 0.77 | MAPT (0.56) | SMN1; SMN2HPGDGAAMEN1KMT2A | |
| SCHEMBL19434752 | 0.77 | MAPT (0.56) | SMN1; SMN2HPGDGAAMEN1KMT2A | |
| SCHEMBL16224346 | 0.77 | KMT2A (0.57) | SMN1; SMN2HPGDLRRK2MEN1KMT2A | |
| SCHEMBL17560854 | 0.77 | KMT2A (0.57) | SMN1; SMN2HPGDLRRK2MEN1KMT2A | |
| SCHEMBL19449735 | 0.76 | GAA (0.58) | SMN1; SMN2HPGDGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566012-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD (AU) | 2023-01-31 | — | — | US | claimed |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2021-01-14 | — | — | US | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| EP-3188722-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | Neoculi Pty Ltd (AU) | 2017-07-12 | — | — | EP | claimed |
| WO-2016033635-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566012-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885HPGD 232/4885LRRK2 4861/4885 |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885HPGD 232/4885LRRK2 4861/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885HPGD 232/4885LRRK2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.